Cytokine Release Syndrome clinical trials at UCSF
1 research study open to eligible people
Cytokine release syndrome is when the immune system releases many inflammatory signals that can make people very sick. UCSF is running clinical trials that combine immune therapies with chemotherapy for relapsed blood cancers. UCSF is tracking symptoms, lab tests, and drug levels to describe the syndrome.
Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
open to eligible people ages 18 years and up
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
San Francisco, California and other locations
Last updated: